Open AccessMenopausal hormone therapy and heart disease prevention: desired or valid?
Author(s) -
В. И. Подзолков,
А. Е. Брагина,
Н. М. Подзолкова
Publication year - 2019
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2019-3-94-106
Subject(s) - medicine , menopause , observational study , hormone therapy , disease , hormone replacement therapy (female to male) , estrogen , estrogen therapy , estrogen replacement therapy , window of opportunity , intensive care medicine , gynecology , physical therapy , breast cancer , cancer , real time computing , computer science , testosterone (patch)
Cardiovascular diseases are the main cause of death for women in older age groups. For many decades, specialists have tried to prevent their development by the use of estrogen. The review of the literature presents current data on the effect of menopausal hormone therapy (MHT) on the risk of cardiovascular complications. The results of the main randomized clinical and observational studies in this area, conducted over several decades, are discussed. We described the concept of “window of opportunities”, in accordance with which an improvement in cardiovascular prognosis can be expected only at the onset of MHT in women under the age of 60 years in early postmenopause (menopause duration <10 years). There are experimental and clinical data explaining the different effects of estrogen on the cardiovascular prognosis in women of various age groups and different duration of postmenopause. The recommendations given in the review on the use of MHT are based on modern international guidelines.